Concepedia

Sara Manglaviti

SM

Statistics

Publications

16

Citations

351

H-Index

12

Active since

2020

Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

University of Milan

Politecnico di Milano

Mario Negri Institute for Pharmacological Research

Sara Manglaviti is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in oncology, medicine, and immunotherapy.

ORCID

Publications per year

2020–2024

16

Publications

16

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

Arsela Prelaj, Achille Bottiglieri, Claudia Proto et al. · European Journal of Cancer · 2021 · 58 citations

, , +16

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

Arsela Prelaj, Edoardo Gregorio Galli, V. Miskovic et al. · Frontiers in Oncology · 2023 · 36 citations · Full text

, , +17

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy

Arsela Prelaj, Mattia Boeri, Alessandro Robuschi et al. · Cancers · 2022 · 31 citations · Full text

, , +17

Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

Claudia Proto, M. Ganzinelli, Sara Manglaviti et al. · Annals of Oncology · 2024 · 31 citations · Full text

, , +14

STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines

Claudia Proto, Sara Manglaviti, Giuseppe Lo Russo et al. · Journal of Thoracic Oncology · 2023 · 27 citations · Full text

, , +6

1–5 of 16